The Large myd mouse has a loss-of-function mutation in the putative glycosyltransferase gene Large. Mutations in the human homolog (LARGE) have been described in a form of congenital muscular dystrophy (MDC1D). Other genes (POMT1, POMGnT1, fukutin, and FKRP) that encode known or putative glycosylation enzymes are also causally associated with human congenital muscular dystrophies. All these diseases are associated with hypoglycosylation of the membrane protein ␣-dystroglycan (␣-DG) and consequent loss of extracellular ligand binding. Hence, they are termed dystroglycanopathies. A paralogous gene for LARGE (LARGE2 or GYLTL1B) may also have a role in DG glycosylation. Using database interrogation and reverse-transcriptase polymerase chain reaction (RT-PCR), we identified vertebrate orthologs of each of these LARGE genes in many vertebrates, including human, mouse, dog, chicken, zebrafish, and pufferfish. However, within invertebrate genomes, we were able to identify only single homologs. We suggest that vertebrate LARGE orthologs be referred to as LARGE1. RT-PCR, dot-blot, and northern analysis indicated that LARGE2 has a more restricted tissue-expression profile than LARGE1. Using epitope-tagged proteins, we show that both LARGE1 and LARGE2 localize to the Golgi apparatus. The high similarity between the LARGE paralogs suggests that LARGE2 may also act on DG. Overexpression of LARGE2 in mouse C2C12 myoblasts results in increased glycosylation of ␣-DG accompanied by an increase in laminin binding. Thus, there may be functional redundancy between LARGE1 and LARGE2. Consistent with this idea, we show that ␣-DG is still fully glycosylated in kidney (a tissue that expresses a high level of LARGE2 mRNA) of Large myd mutant mice.
Introduction
Mutations in at least six genes encoding known or putative glycosylation enzymes are associated with muscular dystrophies or myopathies (Hewitt and Grewal, 2003; Martin and Freeze, 2003) . The majority of these disorders are severe congenital forms, often associated with brain and eye abnormalities. Muscle-eye-brain disease (MEB), Fukuyama-type congenital muscular dystrophy, and Walker-Warburg syndrome (WWS) are associated with mutations in the genes POMGnT1, fukutin, or POMT1 (Kobayashi et al., 1998; Yoshida et al., 2001; Beltrán-Valero de Bernabé et al., 2002) . Mutations in the gene encoding fukutin-related protein (FKRP) result in a wide spectrum of clinical phenotypes ranging from the severe congenital muscular dystrophies Type 1C (MDC1C), MEB, and WWS to the milder limb-girdle muscular dystrophy 2I (LGMD2I) (Mercuri et al., 2003; Beltrán-Valero de Bernabé et al., 2004) . The Large gene, which encodes a putative bifunctional glycosyltransferase, is mutated in the myodystrophy (Large myd ) mouse (Grewal et al., 2001 ) and in congenital muscular dystrophy Type 1D (MDC1D) (Longman et al., 2003) .
All these human diseases, and the Large myd mouse, are associated with hypoglycosylation of the muscle membrane protein α-dystroglycan (α-DG) and concomitant loss of extracellular ligand binding (Grewal et al., 2001; Michele et al., 2002) . Many of the clinical findings can be recapitulated in the muscle and brain of mice by conditional depletion of DG (Côté et al., 1999; Moore et al., 2002) , indicating that this protein is a key downstream target. Hence, these muscular dystrophies are now commonly termed dystroglycanopathies (Michele and Campbell, 2003) . Altered glycosylation of α-DG might also play a role in cancer, as hypoglycosylation of the protein and loss of laminin binding have been demonstrated in invasive carcinoma cells (Singh et al., 2004) .
α-and β-DG are essential components of the dystrophinglycoprotein complex (Ervasti and Campbell, 1991; Ibraghimov-Beskrovnaya et al., 1992) , which in muscle links dystrophin and the actin cytoskeleton inside the cell to the extracellular matrix. Both subunits are encoded by a single pro-peptide that is proteolytically cleaved; the subunits remain associated through non-covalent interactions (Michele and Campbell, 2003) . α-DG is highly glycosylated in a tissue-specific manner with both N-and O-linked glycans, and the carbohydrate can amount to over half of its molecular mass. These O-linked structures are necessary for binding of DG to extracellular ligands such as laminin and agrin (Martin, 2003) . β-DG is a membrane protein with less extensive glycosylation that is limited to N-linked glycans.
DG is widely expressed, with roles in muscle stabilization, cell migration, basement membrane assembly, and signaling (Winder, 2001) . Homologs have been identified in a range of organisms including mammals (Ibraghimov-Beskrovnaya et al., 1992) , chicken (Brancaccio et al., 1995) , zebrafish (Parsons et al., 2002) , Xenopus (Cohen et al., 1995) , Drosophila (Greener and Roberts, 2000) , and nematodes (Grisoni et al., 2002) .
LARGE was originally named because it covers approximately 650 kb of human genomic DNA (Peyrard et al., 1999) , despite a coding region only 2268 bp. The predicted protein structure contains an N-terminal cytoplasmic domain, a transmembrane region, a coiled-coil motif, and two putative catalytic domains (Grewal et al., 2001) . The proximal catalytic domain has closest homology to Waaj, a bacterial family GT8 glycosyltransferase (Coutinho et al., 2003) involved in lipooligosaccharide synthesis (Heinrichs et al., 1998) . The distal domain shows the most similarity to human UDP-GlcNAc:Galβ1,3-N-acetylglucosaminyltransferase (iGnT), a family GT49 glycosyltransferase (Coutinho et al., 2003) responsible for synthesis of the poly-N-acetyllactosamine-based erythrocyte i antigen (Sasaki et al., 1997) . It has recently been shown that overexpression of LARGE in cell lines derived from patients with WWS and MEB results in hyperglycosylation of α-DG and restoration of lamininbinding activity to the protein . As the loss of ligand binding activity by α-DG appears to contribute significantly to the pathology of these diseases, up-regulation of LARGE activity might represent a therapeutic approach for these muscular dystrophies .
We previously reported a mouse gene closely related to Large (Large-like) identified using a BLAST search of mouse genome sequences . This gene is also referred to as Gyltl1b (GenBank Accession number NM_152312) (Brockington et al., 2005) or LARGE2 (Fujimura et al., 2005) . In this article, we report the gene structures, evolutionary conservation, and the expression profiles of LARGE and LARGE2. In addition, epitope-tagged LARGE and LARGE2 proteins are both shown to localize to the Golgi apparatus, consistent with a function in glycosylation. Transient overexpression of Large2 in the C2C12 mouse myoblast cell line results in an increase in α-DG glycosylation and laminin binding.
Results

LARGE is part of a highly conserved gene family
We previously reported a mouse gene closely related to Large identified by BLAST searches of mouse genome sequences . We initially named this gene Large-like; it is also now known as Gyltl1b (GenBank Accession number NM_152312) or LARGE2 (Fujimura et al., 2005) . We confirmed the complete coding sequences of human and mouse LARGE2 by sequencing reverse-transcriptase polymerase chain reaction (RT-PCR) products amplified from kidney and testis RNA (GenBank Accession numbers AY742914 and AY742915 for mouse and NM_152312 for human). We then used database interrogation to identify homologs of both genes from other organisms. RT-PCR was used to confirm the full-length coding sequences of LARGE and LARGE2 from zebrafish (AY662338 and AY662339) and chicken (AY662336 and AY662337). Within invertebrate genome sequences, we were able to identify single homologs in the nematode worms Caenorhabditis elegans (Peyrard et al., 1999) and C. briggsae (data not shown), and in the honeybee Apis mellifera. However, no homolog was found in the Drosophila genome. Until their biochemical functions are defined, we propose the generic name LARGE for this family with the paralogous genes referred to as LARGE1 and LARGE2. The invertebrate homolog is therefore defined as LARGE. A ClustalX alignment of the predicted amino acid sequences of all the vertebrate homologs and the honeybee LARGE protein is shown in Figure 1 . We were unable to establish the 5′ coding region of the bee gene with certainty, and therefore, this has been omitted from the alignment.
The predicted LARGE1 and LARGE2 proteins have a similar domain structure; they are type II membraneanchored proteins with short (eight to ten amino acids) N-terminal cytoplasmic tails, short (16-23 amino acids) transmembrane domains, variable stem regions, and two catalytic domains. The ClustalX alignment shows the extensive amino acid similarity between paralogous vertebrate LARGE proteins over the catalytic domains (for example, mouse Large1 and Large2 share 68% amino acid identity). The conservation between species is also high; honeybee LARGE has ∼53% amino acid identity with the other homologs over the catalytic domains. The MDC1D case reported by Longman et al. (2003) is a compound heterozygote for a truncating and a missense mutation (Glu509Lys) within the second catalytic domain. We note that Glu509 (indicated by a diamond in Figure 1 ) is conserved in all the LARGE homologs we identified, including the bee protein.
In Figure 1 , the level of amino acid conservation between the LARGE proteins appears much lower over the N-terminal and transmembrane regions. Close examination of the alignment shows that the mammalian LARGE2 proteins, which lack predicted coiled-coil domains, show little similarity to LARGE1 in the N-terminal cytoplasmic and transmembrane regions. In contrast, the other vertebrate LARGE2 proteins have predicted coiled-coil domains and have N-terminal regions similar to the LARGE1 proteins. Figure 2 shows a rooted maximum likelihood tree based on the ClustalX alignment of the amino acid sequences of the predicted catalytic domains of the LARGE family proteins. The vertebrate LARGE1 and LARGE2 proteins each form a separate cluster within this tree, indicating they originated from a gene-duplication event in the vertebrate lineage.
LARGE1 and LARGE2 arose via a gene-duplication event
We then determined the gene sizes, locations, and exon organization for these genes, on the basis of available genomic sequence data (Table I, Figure 3 ). Owing to poor reliability of gene prediction programs for 5′ UTRs and low coverage of EST data for most species, only the coding exons are shown in Figure 3 . However, we note that as both the human and mouse LARGE1 genes have introns of at least 100 kb within their 5′ UTRs, this figure probably significantly underestimates gene sizes. There is currently insufficient genomic sequence in the zebrafish assembly to determine the complete gene structure, and therefore, we have included the predicted puffer fish (Takifugu rubripes) genes instead. In general, there is a striking difference in gene size between the paralogs, for example the human LARGE1 gene is over 100-fold bigger than LARGE2, and this difference is because of significantly greater intron sizes in all the LARGE1 homologs.
Where possible, we also determined the chromosomal location of each gene (Table I) . Comparison of the gene locations with regions of conserved gene synteny shows Fig. 1 . ClustalX alignment of LARGE homologs. Predicted amino acid sequences of the orthologs of LARGE (designated LARGE1) and of LARGE2 were aligned using ClustalX. Identical residues in all proteins in the alignment are shown in white text on black. Conserved (white on dark gray) and similar residues (black on light gray) are calculated at a 60% threshold. The locations of predicted protein domains are shown under the alignment. The arrowheads indicate the region missing in the mouse protein due to recent intron formation in rodents. The diamond indicates the location of the Glu509Lys mutation in the MDC1D patient (Longman et al., 2003) . Asterisks denote DxD motifs, characteristic of many glycosyltransferase catalytic domains (Wiggins and Munro, 1998) . Am, Apis mellifera (honey bee); Cf, Canis familiaris (dog); Dr, Danio rerio (zebrafish); Gg, Gallus gallus (chicken); Hs, Homo sapiens (human); Mm, Mus musculus (mouse).
that all the mammalian and chicken LARGE1 genes map to homologous genomic locations, as do the LARGE2 genes (Table I ). This confirms that vertebrate LARGE1 and LARGE2 genes are true paralogs that arose via a geneduplication event.
As expected for a gene duplication, the regions encoding the two predicted catalytic domains show a very similar organization in all the vertebrate genes; they all span 12 exons and have intron boundaries occurring at equivalent locations ( Figure 3 ). However, from examination of both the alignments and the genomic organization, it is apparent that the mammalian LARGE1 orthologs lack the exon encoding the coiled-coil domain. All the other vertebrate genes investigated in this study encode this domain, as do the frog Xenopus laevis and X. tropicalis LARGE2 genes (data not shown). Furthermore, the chromosomal position of chicken LARGE2 is homologous to the human and mouse LARGE2 gene locations, indicating they are true orthologs. Together with the lack of conservation of both amino acid sequence and intron locations at the 5′ end of the genes, this suggests that the mammalian LARGE2 genes have acquired an alternative initial coding exon and that Figure 1) . Although an openreading frame has been maintained across this intron, it is spliced in all the RT-PCR products we obtained. The intron is also present and correctly spliced in the rat Large2 gene (data not shown), indicating the formation of this intron occurred within the rodent lineage.
Large2 is alternatively spliced in mouse
From mouse EST information, we identified a potential alternative splice form of Large2 that lacks one of the exons encoding the first catalytic domain (indicated by an asterisk in Figure 3 ). This alternative splicing was confirmed by RT-PCR in mouse testis and kidney RNA with products of 473 and 368 bp ( Figure 4 ) and sequencing of the PCR products confirmed the exon was excluded. However, only one human EST was identified that lacked this exon and we were unable to amplify this alternative transcript from human RNA ( Figure 4A ). Therefore, the functional significance of this alternative splicing in the mouse is currently unclear. Exclusion of this exon does not alter the reading frame, but removes a highly conserved 35-amino acid region (residues 193-227 of mouse Large2). We found no evidence, either by RT-PCR or from examination of EST databases, for alternative splicing of this region of LARGE1 in either human or mouse.
LARGE1 and LARGE2 have different tissue-expression profiles
We compared the tissue profiles of Large1 and Large2 mRNAs in mouse by RT-PCR ( Figure 4B ). In agreement with previous work (Peyrard et al., 1999) , we found that Large1 is expressed in a range of adult tissues. Large1 is also expressed during mouse embryogenesis; the earliest time-point studied was 7 dpc and we were also able to amplify the transcript in RNA from 12.5 dpc embryos (data not shown). Large2 shows a more restricted pattern of expression in adult tissues than Large1, with high levels in the testis and kidney, but very low expression in the heart and brain. We were unable to detect significant expression in skeletal muscle (quadriceps femoris RNA was used in Figure 4 ). Like Large1, Large2 is expressed during mouse embryogenesis, with RT-PCR products detected from 7 dpc. Dot-blot analysis indicated that human LARGE1 is also widely expressed, with highest levels in brain, heart, skeletal muscle, stomach, bladder, and pancreas ( Figure 4C ). Highest levels of LARGE2 expression were observed in placenta, adult and fetal kidney, pancreas, and prostate and salivary glands. Only low levels of expression were detected in brain or skeletal muscle RNA ( Figure 4C ). This low expression of LARGE2 in human skeletal muscle was confirmed by northern blotting of total RNA ( Figure 4D ). For LARGE1, a 4.5-kb transcript was seen in adult and fetal skeletal muscle, brain, and kidney. For LARGE2, a 2.5-kb transcript was identified in both fetal and adult kidney, with a faint Fig. 2 . Rooted maximum likelihood tree of LARGE proteins. The tree was generated from the ClustalX amino acid alignment using ProML and displayed using Dendromaker. Gapped residues and all those N-terminal of the highly conserved KCE motif (residues 64-66 of human LARGE2) were excluded. Am, Apis melifera (honeybee); Cf, Canis familiaris (dog); Dr, Danio rerio (zebrafish); Gg, Gallus gallus (chicken); Hs, Homo sapiens (human); Mm, Mus musculus (mouse). Large2 and LARGE1 proteins both localize to the Golgi apparatus As no antibodies to the endogenous proteins are currently available, the complete coding regions of mouse Large2 and human LARGE1 (clones containing the full-length mouse Large1 coding sequence were unstable in Escherichia coli) were fused in-frame to EGFP or DsRed2. The coding sequence of the mutated transcript of Large myd mice, which would encode a truncated Large protein consisting of the cytoplasmic, transmembrane, and coiled-coil domains, was amplified by RT-PCR from skeletal muscle RNA and was also used to generate fusion proteins. Localization of the epitope-tagged proteins was investigated in normal rat kidney fibroblasts (NRK cells) and the mouse myoblast cell line C2C12 using immunofluorescence ( Figure 5 ). The Golgi markers used were α-mannosidase II (Velasco et al., 1993) in NRK cells and either golgin 97 (Kjer-Nielsen et al., 1999) or GM130 (Nakamura et al., 1995) in C2C12 cells.
In NRK cells, the Large2-EGFP fusion protein is targeted to the Golgi, as shown by co-localization with α-mannosidase II ( Figure 5 ). We saw a similar localization pattern for LARGE1-EGFP (data not shown). In transfected C2C12 myoblasts, both Large2-EGFP and LARGE1-EGFP showed co-localization with golgin 97 (data not shown) and GM130 ( Figure 5 ). Thus, although our expression data suggest that Large2 is not normally expressed in skeletal muscle, the protein is capable of localizing to the Golgi in myoblasts.
The truncated Large myd protein product [Large1(myd), Figure 5 ] also localized to the Golgi when C-terminally tagged, indicating that the N-terminal 143 residues of the protein are sufficient for correct targeting and retention. Co-transfection of Large1(myd)-DsRed2 and Large2-EGFP constructs showed complete co-localization of the two proteins, confirming the correct localization of the mutant protein. We found that N-terminal tagged protein did not localize to the Golgi (Figure 5 ), instead showing a diffuse staining consistent with retention in the endoplasmic reticulum (ER). Presumably, the tag interferes with correct folding and/or targeting of the protein in this configuration.
To confirm the Golgi localization of the tagged proteins, cells were treated with brefeldin A (BFA), which causes many Golgi enzymes to redistribute to the ER (Doms et al., 1989; Lippincott-Schwartz et al., 1989) . After treatment, both LARGE1-EGFP and Large2-EGFP showed a diffuse staining, indicating the proteins had been redistributed to the ER. GM130, a cis-Golgi matrix protein, remains associated with Golgi remnants around the nucleus after BFA treatment and does not redistribute to the ER with Golgi enzymes (Nakamura et al., 1995) , resulting in a punctate perinuclear staining. Thus, both LARGE1 and Large2 localize to the Golgi apparatus and show a redistribution pattern typical of Golgi enzymes following BFA treatment. Our data are consistent with both proteins having a role in protein glycosylation and/or processing.
Transient expression of Large2 in myoblasts increases α-DG glycosylation and laminin binding
The high level of amino acid similarity between LARGE1 and LARGE2 suggests the latter may also act in the DG glycosylation pathway. To investigate this, we used the C2C12 myoblast cell line and the monoclonal antibody IIH6, which recognizes glycosylated α-DG. C2C12 cells can be readily differentiated into myotubes, and this is accompanied by increased DG expression and generation of glycosylated forms of α-DG that can be detected by IIH6 antibody (Campanelli et al., 1994; Gee et al., 1994) . C2C12 myoblasts and differentiated myotubes express Large1 but not Large2 (data not shown). Overexpression of LARGE1 in myoblasts results in hyperglycosylation of α-DG . Therefore, to test whether Large2 was able to alter α-DG glycosylation, we transfected C2C12 myoblasts with the mouse Large2 coding sequence cloned into the pcDNA3.1V5-His vector.
Figure 6(A) shows western blots of protein extracts from mouse skeletal muscle (positive control) and transfected and non-transfected C2C12 myoblasts. β-DG was used as a loading control. Using IIH6, we saw the typical "smear" of α-DG at 140-200 kD in mouse skeletal muscle and a positive signal of about 120-130 kD in our non-transfected C2C12 myoblast cell line. This positive signal in myoblasts also shows laminin-binding activity by overlay assay (Figure 6A ) and probably corresponds to partially glycosylated DG. Myoblasts transfected with Large2 showed increased IIH6 immunoreactivity of mass 150-250 kD, which we presume corresponds to increased glycosylation of α-DG. This increase in IIH6 immunoreactivity is concomitant with an increase in laminin binding on overlay assay ( Figure 6A ) and indicates that Large2 is also able to act in the DG glycosylation pathway.
The high level of sequence similarity between LARGE1 and LARGE2, the different expression profiles, and the ability of both proteins to increase glycosylation of α-DG suggests they may have tissue-specific roles in DG glycosylation. Furthermore, there may be functional redundancy between the two genes. Western analysis of a range of tissues from control and Large myd mice showed correlation between preservation of DG glycosylation (indicated by retention of immunoreactivity with IIH6 and VIA4 antibodies) and high levels of Large2 expression. Figure 6 (B) shows a VIA4 immunoblot; Large myd kidney tissue shows a strong positive signal with this antibody, in contrast to the other tissues where VIA4 immunoreactivity is significantly reduced or absent. 
Discussion
The similarity in sequence and genomic organization of LARGE1 and LARGE2 suggests that that the two genes arose from duplication of an ancestral gene. From examination of genome databases and RT-PCR analysis, we have identified homologs of LARGE1 and LARGE2 in mammals, fish, and chicken genomes. This indicates that duplication of the ancestral LARGE gene occurred at least 450 million years ago, prior to the divergence of mammals, avians, and ray-finned fishes from their common ancestor (Kumar and Hedges, 1998) . We searched extensively for further homologs of LARGE in these organisms employing a variety of bioinformatic approaches, but did not find any. Thus, this family of putative glycosyltransferases appears to contain only two members in vertebrates. For the mammalian LARGE1 and LARGE2 genes, the amino acid similarity between paralogs is confined to the two predicted catalytic domains. This appears to be due to acquisition of a novel initial coding exon by the mammalian LARGE2 genes, because in other vertebrate orthologs, the similarity with LARGE1 extends over the whole protein including the N-terminal cytoplasmic, transmembrane, and coiled-coil domains. With the exception of Fugu, all the vertebrate LARGE1 genes are 40-to 100-fold bigger than their LARGE2 paralogs. This difference is due to the much bigger introns in the LARGE1 orthologs. There is some evidence that important regulatory regions for Large1 are widely dispersed: a mutant allele of Large caused by a transgene insertion 160 kb downstream of the gene has recently been reported (Levedakou et al., 2005) . This insertion results in silencing of Large, and homozygous mutant mice have a phenotype closely resembling the Large myd mutation.
For mouse Large2, we identified alterative splicing within the part of the gene encoding the first catalytic domain. However, the functional consequences and significance of excluding this exon are unclear as RT-PCR data suggest this alternative splicing is not conserved in human ( Figure 4A ). Alternative splicing of 5′ UTR exons appears relatively common within glycosyltransferase genes and may be related to translational control (Martinez-Duncker et al., 2004) or use of tissue-specific promoters Falkenberg et al., 2003) . However, only a few splice variants that produce mRNAs with different proteinencoding capabilities have been described in the literature. For example, the mouse α1,2-galactosyltransferase gene generates four mRNA isoforms that differ within the stem region (Joziasse et al., 1992) .
We show that epitope-tagged LARGE1 and Large2 both localize to the Golgi apparatus and that the N-terminal 143 amino acids are sufficient for correct targeting and retention. It is possible that the LARGE1 and LARGE2 proteins act together as a complex, as has been demonstrated for the mammalian and Drosophila POMT1 and POMT2 mannosyltransferases (Ichimiya et al., 2004; Manya et al., 2004) and for the EXT1 and EXT2 glycosyltransferases involved in heparan sulfate synthesis (McCormick et al., 2000) . However, this seems unlikely since RT-PCR and dot-blot analyses of LARGE1 and LARGE2 show very different tissue-expression profiles. In addition, overexpression of each gene independently is sufficient to increase DG glycosylation.
Currently, the biochemical activities of LARGE and LARGE2 are still unknown. However, there is now a substantial body of evidence for a functional role for LARGE1 in DG glycosylation (Grewal et al., 2001; Michele et al., 2002; Barresi et al., 2004; Kanagawa et al., 2004; Patnaik and Stanley, 2005) . Of the other genes associated with dystroglycanopathies, POMT1 and POMGnT1 are probably involved in O-mannosylation (Zhang et al., 2002; Manya et al., 2004) , but the biochemical activities of fukutin and FKRP are unknown. In cells deficient in POMT1, POMGnT1, or fukutin, forced expression of LARGE still results in hyperglycosylation of α-DG , indicating that, at least in this experimental overexpression system, LARGE may act in a different glycosylation pathway. Overexpression studies in CHO cells defective for a number of steps in glycan synthesis suggest that LARGE1 can modify both N-and O-glycans (Patnaik and Stanley, 2005) . On the basis of homologies of the catalytic domains, both LARGE1 and LARGE2 might add a repeated glycan structure such as poly-N-acetyllactosamine, which can be attached to N-glycans, O-glycans, and glycolipids (Ujita and Fukuda, 2001) . It is clear that determination of the biochemical activity of LARGE will be a key step toward determining its relationship to the other glycosylation proteins associated with dystroglycanopathies. DG is a widely expressed, essential glycoprotein (Henry and Campbell, 1999) . Null mutations of DG in the mouse are embryonic lethal at very early stages of development (Williamson et al., 1997) , as are engineered fukutin (Takeda et al., 2003) and POMT1 (Willer et al., 2004 ) null mice; yet homozygous Large myd mice are viable and only a restricted number of issues are affected (Holzfeind et al., 2002) . We speculate that partial functional redundancy between Large1 and Large2 might account for the relatively mild phenotype of the Large myd mouse. For example, glycosylation of DG is preserved in the kidney, a tissue that normally expressed high levels of Large2 mRNA in homozygous mutant mice. Overlapping functions have been postulated for other glycosylation genes such as the UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyl-transferases (Ten Hagen et al., 2003) and could have implications for development of therapeutic strategies for muscular dystrophy. As the overexpression of LARGE1 can restore IIH6 immunoreactivity and laminin-binding activity to α-DG in cells from patients with mutations in distinct genes, up-regulation of this gene might be applicable to different dystroglycanopathies . Our data suggest that LARGE2 should be considered an additional potential therapeutic target because it is also able to increase DG glycosylation in myoblast cells.
Materials and methods
Database and bioinformatics analysis
Blast searches of Ensembl genomic assemblies (http:// www.ensembl.org) were used to locate genes. Genomic and EST sequences were assembled using Sequencher software (Gene Codes Corporation, Ann Arbor, MI). Gene structures were then predicted with a combination of Ensembl gene predictions, BLAST searches, and Nucleotide Identity of X analysis (http://www.rfcgr.mrc.ac.uk). A ClustalX multiple protein sequence alignment (bios.u-strasb.fr) was generated using predicted amino acid sequences for the LARGE homologs. The alignment is displayed using Mac Boxshade (iubio.bio.indiana.edu). Transmembrane, coiled-coil, and catalytic domain predictions were made using Protein Identity of X analysis (http://www.rfcgr.mrc.ac.uk). The maximum likelihood tree was generated using the ProML program within the Phylip suite of programs (evolution.gs.washington.edu/ phylip/) and displayed using Dendromaker (http:// www.cib.nig.ac.jp/dda/timanish/dendromaker/ home.html).
Confirmation of coding sequences and expression analysis
For RT-PCR amplification, RNA was isolated from tissues or embryos using TRIZOL (Invitrogen, Paisley, Scotland) or purchased from Ambion (Huntingdon, Cambs, UK). First-strand cDNA was synthesized using oligodT primers and an ImPROM-II cDNA synthesis kit (Promega, Madison, WI). Gene-specific primers were then used in PCR to generate overlapping products (sequences supplied on request). PCR products were then subcloned into pT-EASY (Promega) and sequenced, allowing assembly of full coding sequences. For RT-PCR expression analysis in mouse, primer sequences used were: LargeF2 5′-TTCCTGGCT-GCCTCTTTGAC-3′ and LargeR2 5′-TGGACGTGT-GTTTTTCCAGA-3′; Large2F2 5′-CCAGGCTCTCA-CACCCTACG-3′ and Large2R2 5′-GGACACCCTGGT-CAGCCTCT-3′. For both primer pairs, an annealing temperature of 60°C was used with 30 cycles of amplification. To test for alternative splicing of Large2, we used primers AltspliceF 5′-ACTCTTCCGAACATGGATGG-3′ and AltspliceR 5′-GACCGCATTGAAGATGTCCT-3′. In mouse, these primers amplify a product of 472 bp if exon 7 is included in the mRNA and a product of 367 bp if it is omitted. For human, we used primers HLarge2f 5′-GCCA-GAAACATCCTGGAGAC-3′ and HLarge2r 5′-TCA-CAGCGTTGAAGATGTCC-3′. An annealing temperature of 64°C was used with 30 amplification cycles.
The tissue distributions of human LARGE1 and LARGE2 mRNAs were investigated by hybridizing multiple-tissue RNA dot-blots (Clontech, San Diego, CA) with radiolabeled gene-specific cDNA probes. The probes corresponded to 679-1433 bp of GenBank Accession number NM_004737 for LARGE1 or to 582-1385 bp of GenBank Accession number NM_152312 for LARGE2. Filters were washed in 0.2× SSC at 65°C and exposed for 72 h. A northern blot containing 10 µg of total human RNA from several human and fetal tissues (RNA was purchased from Stratagene, La Jolla, CA) was hybridized using the same probes and conditions. Construct generation and transient transfections PCR (using Proofstart Taq polymerase, Qiagen, Crawley, Sussex, UK) was used to amplify the complete coding regions of human LARGE and mouse Large2 from cDNA clones. The PCR products were then subcloned into the SalI/SacII sites of pEGFP-N1 and pDsRed2-N1 (Clontech) to make C-terminal fusion proteins. The complete openreading frame of the mutant mRNA product in the Largemyd mouse was amplified by RT-PCR and cloned into the EcoRI/BamHI sites of pEGFP-N1 or pDsRed2-N1. This Large myd product was also cloned into pEGFP-C1 to make an N-terminal fusion. For the transient expression of Large2 protein in C2C12 cells, the full-length coding region was amplified and cloned in-frame into the SalI/SacII sites of pcDNAV5His (Invitrogen). All primer sequences will be supplied on request. All constructs were fully sequenced on both strands to ensure that they did not contain polymerase errors.
NRK cells or C2C12 myoblasts were grown and maintained (5% CO 2 , 37°C) in DMEM supplemented with 10% fetal calf serum and transfected using Effectene transfection reagent (Qiagen). For immunocytochemistry, cells were seeded onto glass coverslips. Twenty hours after transfection, the cells were washed and fresh media added. Forty-eight hours after transfection, cells were either treated for immunocytochemistry or harvested for western blot analysis. Protein extraction from cell lines or tissues and western blotting was carried out as described previously (Grewal et al., 2001) .
Immunocytochemistry
Transfected cells were fixed with 4% paraformaldehyde in PBS. To determine the effect of BFA treatment, cells were incubated with BFA (10 µg/ml) for 30 min at 37°C immediately prior to washing and fixing with paraformaldehyde. The cells were then treated for 10 min on ice with 0.5% Triton X-100 in PBS, washed with PBS, and then incubated for 30 min at room temperature with 2% goat serum and 10 mg/ml BSA in PBS. Following incubation with primary antibody for 1 h, cells were washed with PBS, then incubated for 1 h with 1:500 dilution of rhodamine Red-X-labeled goat anti-mouse IgG antibody (Molecular Probes, Leiden, The Netherlands). Finally, cells were mounted in VectaShield mounting medium with DAPI. Primary antibodies were used at the following dilutions: α-mannosidase II (53FC3, Covance, Cambridge, Cambs, UK) at 1:10,000, golgin97 (Molecular Probes) at 1:25, and GM130 (BD Biosciences, San Diego, CA) at 1:500.
Images were examined using a Zeiss LSM510uv Combi META confocal attached to a Zeiss Axiovert 100 microscope. Image acquisition and processing were performed using Zeiss LSM software. Images were imported into Photoshop (Adobe) for generation of figures.
